SAGE - BofA downgrades Sage to underperform cites failed Parkinson's study
2024-04-17 11:14:48 ET
More on Sage Therapeutics
- SAGE Therapeutics, Inc. (SAGE) Q4 2023 Earnings Call Transcript
- Sage Therapeutics, Inc. 2023 Q4 - Results - Earnings Call Presentation
- Sizing Up Sage Therapeutics
- Sage drops after mid-stage setback for Parkinson’s disease candidate
- Sage Therapeutics GAAP EPS of -$0.55 beats by $0.76, revenue of $77.97M beats by $16.99M